Capricor Therapeutics Faces Securities Class Action Over Deramiocel Data

The complaint alleges that Capricor altered its statistical analysis plan for Deramiocel without prior FDA approval before resubmitting its Biologics License Application. This shift reportedly masked significant risks regarding the drug's effectiveness, leading to false and misleading statements throughout the class period. When the discrepancy surfaced, the stock price decline resulted in substantial losses for shareholders.

Legal representatives Brian Schall and David Schwartz are inviting affected investors to discuss potential lead plaintiff appointments before the September 28, 2026, deadline. While lead plaintiff status is not required to participate in a potential recovery, those who do not take action remain absent class members until formal certification occurs. Interested parties can reach the firm at its Los Angeles office or via their website to review their rights in this pending litigation.